June 2017-Bayesian Methods in Pharmaceutical Development and Clinical Trial Design presented by Scott Berry

Aug 2017 – Bayesian Disease Progression Modeling in Clinical Trial Design presented by Melanie Quintana

Oct 2017 -BMA-Mod : A Bayesian Model Averaging Strategy for Determining Dose-Response Relationships in the Presence of Model Uncertainty presented by Larry Gould

Jan 2018-The Value of Bayesian Approaches in the Regulatory Setting: Lessons from the Past and Perspectives for the Future presented by Telba Irony

Mar 2018 – Design and analysis of non-inferiority trials: some frequentist and Bayesian perspective presented by Samiran Ghosh

Aug 2018 – Bayesian sample size determination methods for hypotheses testing presented by Sujit Ghosh

Oct 2018 – Unified Screening for Potential Elevated Adverse Event Risk and Other Associations presented by Larry Gould

Dec 2018 – BOIN: a Novel Platform for Designing Early Phase Clinical Trials presented by Ying Yuan

Feb 2019 – Case Studies in Calibrating Hierarchical Model Priors presented by Kert Viele

Mar 2019 – Bayesian Biopharmaceutical Applications using PROC MCMC and PROC BGLIMM presented by Fang Chen

Jul 2019 – Nonclinical Bayesian projects AZ presented by Steven Novick

Aug 2019 – Why Bother with Bayes presented by Thomas Louis

Sep 2019 – Why Bayes for Clinical Trials presented by Frank Harrell

Oct 2019 – Benefit Risk Assessment Using Bayesian Discrete Choice Experiment presented by Saurabh Mukhopadhyay

Nov 2019 – Use of Historical Data in Clinical Trial: An Evidence Synthesis Approach presented by Satrajit Roychoudhury (Pfizer Inc) and Sebastian Weber (Novartis)

Aug 2020 – DIA KOL Lectures presented by Alex Karanevich, PhD (EMB Statistical Solutions); Hengrui Sun, DrPH, MD (FDA); Joe Marion, PhD (Berry Consultants)

Sept 2020 – A Bayesian Sequential Design for COVID-19 Vaccine Trials presented by Rajat Mukherjee

Oct 2020 – Incorporate External Control Data in New Clinical Trial Design and Analysis presented by Lanju Zhang, PhD (AbbVie)

Nov 2020 – Leveraging External Evidence in Medical Device Decision-Making presented by Ram Tiwari

Dec 2020 – Statistical considerations for trials that study multiple indications presented by Brian Hobbs; Emily Zabor; Alexander Kaizer

Feb 2021 – Strategies for improving the assessment of the probability of success in late stage drug development presented by Lisa Hampson and Björn Holzhauer

Mar 2021 – Historical control data borrowing for non-inferiority assessment presented by Hui Quan

Apr 2021 – Bayesian multivariate probability of success with strict control of type I error presented by Matt Psioda and Ethan Alt

Jun 2021 – Bayesian detection of potential safety signal from blinded clinical trial data presented by Saurabh Mukhopadhyay and Brian Waterhouse

Aug 2021 – Bayesian Model Averaging of Longitudinal Dose Response Models presented by Richard Payne

Oct 2021 – Bayesian Shared Parameter Analysis of Mortality and Function within an Adaptive Platform Trial for ALS presented by Melanie Quintana

Nov 2021 – Use of Bayesian Hierarchical Models in the Presentation of Subgroup Analyses presented by Mark Rothmann

Jan 2022 – Use of external data in randomized clinical trials presented by Heinz Schmidli and Marius Thomas, Novartis

Mar 2022 – Rev. Bayes’ best friend: Markov or Laplace? presented by Krishna Padmanabhan

Apr 2022 – Statistical Designs for Early Phase Oncology Drug Development in the Era of Dose Optimizing for Targeted Therapeutics presented by Yuan Ji

May 2022 – Bayesian Divide-and-Conquer Propensity Score Based Approaches for Leveraging Real World Data in Single Arm Clinical Trials presented by Jian Zhu and Eric Baron

Jul 2022 – A Bayesian Adaptive Trial in Duchenne Muscular Dystrophy presented by Stephen Lake

Aug 2022- Delivering Transformative Medicines to Patients by Leveraging Complex Innovative Designs AMG 592 SLE Case Study presented by Amy Xia, May Mo, Tony Jiang

Aug 2022 – The Epistemological Superiority of Bayesian Inference over Frequentist Inference Inferring What is Likely To Be True presented by Stephen J. Ruberg

Sep 2022 – Case Study of a Phase 3 Study Design with Hybrid Control in 1L DLBCL – FDA Complex Innovative Designs Pilot Program presented by Jiawen Zhu & Herb Pang

Oct 2022 – Learnings from Chronic Pain Master Protocol: FDA Complex Innovative Designs Pilot Program presented by Saptarshi Chatterjee and Phebe Kemmer

Nov 2022 – NEOS: A Bayesian non-inferiority trial design in pediatric multiple sclerosis in the FDA Complex Innovative Designs Pilot Program presented by Marius Thomas & Dieter A Häring

Dec 2022 – CID from pilot program, to program, to common submission presented by Scott Berry

Feb 2023 – Considerations for Bayesian Methods with Informative Priors presented by James Travis

Mar 2023 – Using meta-analyses to guide statistical methodology for clinical dose response studies presented by Neal Thomas

Apr 2023 – The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials presented by Ben Saville

May 2023 – Design and Sample Size Determination for Multiple-dose Randomized Phase II Trials for Dose Optimization presented by Ying Yuan

July 2023 – Why are there not more Bayesian Clinical Trials? Results from a Survey of Clinicians in the Clinical Trial Community presented by Jennifer Clark and Ross Bray